검색어: eradikatsiooniks (에스토니아어 - 영어)

tõstatatud probleemid puudutasid annustamiserinevusi võrreldavate preparaatide h. pylori eradikatsiooniks kasutatavas kolmekordses ravis.
the concerns rose referred to discrepancies in comparison to the reference products on posology of triple therapy for h. pylori eradication.

taotleja peab esitama kliinilised andmed, mis õigustavad 15 mg kapslite kasutamist helicobacter pylori eradikatsiooniks.
the applicant should provide clinical data to support the use of 15 mg capsules for helicobacter pylori eradication.

kui lansoprasooli kasutatakse h. pylori eradikatsiooniks koos antibakteriaalsete ainetega, tuleb järgida ka manustatavate antibiootikumide kasutusjuhiseid.
if lansoprazole, in combination with antibiotics, is used for eradication therapy of h. -pylori, then also instructions for the use of these antibiotics should be followed.

võrdluspreparaadi ravimi omaduste kokkuvõte saksamaal sisaldab helicobacter pylori eradikatsiooniks soovitatud lansoprasooli ja antibiootikumide kombinatsiooni puhul konkreetseid annuseid ja annusegraafikuid.
the spc of the reference product in germany contains specific doses and dosing schedules for the combinations of lansoprazole and antibiotics recommended for eradication of helicobacter pylori.

samuti kombinatsioonis sobivate antibakteriaalsete terapeutiliste raviskeemidega helicobacter pylori eradikatsiooniks ja maohaavandite taastekke ennetamiseks patsientidel h. pylori’ ga seonduvate haavanditega.
lansoprazol abz-pharma (lansoprazole) is a proton pump inhibitor that inhibits gastric acid secretion and is used for treatment of duodenal and gastric ulcer, reflux oesophagitis, gastro-oesophageal reflux disease, treatment and prophylaxis of nsaid-associated gastric and duodenal ulcers, zollinger-ellison syndrome, and in combination with appropriate antibacterial therapeutic regimens for the eradication of helicobacter pylori and prevention of relapse of peptic ulcers in patients with h. pylori associated ulcers.

maastrichti konsensusdokumendis on märgitud, et helicobacter pylori eradikatsiooniks tuleks kasutada lihtsaid raviskeeme, mida hästi talutakse ja millega saavutatakse ravikavatsuse alusel eradikatsioonimäär üle 80%.
the maastricht consensus states that treatment regimens for eradication of h. pylori should be simple, well tolerated and achieve an eradication rate of over 80% on an intention to treat basis.

annustamine ja manustamisviisid • soovituslikud annused helicobacter pylori eradikatsiooniks: konkreetsete soovituste lisamine kasutatavate antibiootikumide kohta • annustamine ja annustamisskeem sümptomaatilise gastroösofageaalse refluksi korral.
dosage recommendation for the eradication of h. pylori differences: inclusion of specific recommendations on the antibiotics to be used

• mao - ja kaksteistsõrmikuhaavandi raviks; • refluksösofagiidi raviks; • refluksösofagiidi profülaktikaks; • helicobacter pylori (h. pylori) eradikatsiooniks samaaegselt h. pyloriga seotud haavandite sobiva antibiootikumiraviga; •
11 benefit/risk consideration based on the documentation submitted by the mah and the scientific discussion within the committee, the chmp considered that the benefit/risk ratio of agopton and associated names is favourable for use relating to: • treatment of duodenal and gastric ulcer • treatment of reflux oesophagitis • prophylaxis of reflux oesophagitis • eradication of helicobacter pylori (h. pylori) concurrently given with appropriate antibiotic therapy for treatment of h.pylori associated ulcers • treatment of nsaid-associated benign gastric and duodenal ulcers in patients requiring continued nsaid treatment • prophylaxis of nsaid-associated gastric ulcers and duodenal ulcers in patients at risk (see section 4.2) requiring continued therapy • symptomatic gastroesophageal reflux disease • zollinger-ellison syndrome.